The Negative Feedback-Loop between the Oncomir Mir-24-1 and Menin Modulates the Men1 Tumorigenesis by Mimicking the “Knudson’s Second Hit”

Ettore Luzi, Francesca Marini, Francesca Giusti, Gianna Galli, Loredana Cavalli, Maria Luisa Brandi*

Metabolic Bone Unit, Department of Internal Medicine, University of Florence, Florence, Italy

Abstract

Multiple endocrine neoplasia type 1 (MEN1) syndrome is a rare hereditary cancer disorder characterized by tumors of the parathyroids, of the neuroendocrine cells, of the gastro-entero-pancreatic tract, of the anterior pituitary, and by non-endocrine neoplasms and lesions. MEN1 gene, a tumor suppressor gene, encodes menin protein. Loss of heterozygosity at 11q13 is typical of MEN1 tumors, in agreement with the Knudson’s two-hit hypothesis. In silico analysis with Target Scan, Miranda and Pictar-Vert softwares for the prediction of miRNA targets indicated miR-24-1 as capable to bind to the 3’UTR of MEN1 mRNA. We investigated this possibility by analysis of miR-24-1 expression profiles in parathyroid adenomatous tissues from MEN1 gene mutation carriers, in their sporadic non-MEN1 counterparts, and in normal parathyroid tissue. Interestingly, the MEN1 tumorigenesis seems to be under the control of a “negative feedback loop” between miR-24-1 and menin protein, that mimics the second hit of Knudson’s hypothesis and that could buffer the effect of the stochastic factors that contribute to the onset and progression of this disease. Our data show an alternative way to MEN1 tumorigenesis and, probably, to the “two-hit dogma”. The functional significance of this regulatory mechanism in MEN1 tumorigenesis is also the basis for opening future developments of RNA antagonism(s)-based strategies in the in vivo control of tumorigenesis in MEN1 carriers.

Introduction

MicroRNAs (miRNAs) are a family of naturally occurring, evolutionarily conserved, small (approximately 19–23 nucleotides), non-protein-coding RNAs that negatively regulate post-transcriptional gene expression. It is estimated that they account for >3% of all human genes and control expression of thousands of mRNAs, with multiple miRNAs targeting for a single mRNA [1]. Recent studies have also supported a role of miRNAs in the initiation and progression of human malignancies [2], as altered expression of miRNAs has been demonstrated in human tumors such as colorectal neoplasia [3], B cell chronic lymphocytic leukaemia [4,5], B cell lymphoma [6], lung cancer [7], breast cancer [8], and glioblastoma [9,10]. The involvement of miRNAs in human cancer is probably due to the fact that >50% of miRNA genes are located at chromosomal regions, such as fragile or common break point sites, and regions of deletion or amplification that are generally involved in tumorigenesis [11].

Multiple Endocrine Neoplasia type 1 (MEN1) syndrome is a rare complex tumor-predisposing disorder inherited in an autosomal dominant manner [12]. MEN1 syndrome is characterized by tumors of the parathyroids, of the neuroendocrine cells, of the gastro-entero-pancreatic tract, and of the anterior pituitary. MEN1 gene, a tumour suppressor gene, whose translation product is the menin protein, is characterized by loss of heterozygosity at 11q13 in MEN1 tumors [12].
In silico analysis with Target Scan, Miranda and Pictar-Vert softwares for the prediction of miRNA targets indicated miR-24-1 as capable to bind preferentially to the 3’UTR of MEN1 mRNA, and also to p27, p16, TGF-beta, and caspase 8, all involved in MEN1 tumorigenesis. In this work, analysis of miR-24-1 expression profiles performed in parathyroid endocrine tissues from MEN1 mutation carriers, in their sporadic non-MEN1 counterparts and in normal parathyroid tissue, showed that the expression profiles of miR-24-1 mRNA and menin protein generate a GRN.

Results

An Evolutionary Conserved Target Sequence for miR-24-1 is Found in the 3’UTR of MEN1 mRNA

The highly structured 832 nt-3’UTR of MEN1 mRNA (Fig. 1A) was screened for complementarity to seed sequences of known miRNAs via a bioinformatic search by using TargetScan prediction (release 6.0) software. A 7mer-m8 seed match was found at nt 599–605 with a context score of 0.06 (Fig. 1B). This miRNA site was conserved in Human, Mouse, Rat, Dog, and Chicken (Fig. 1B). These data were confirmed by miRanda and PicTar algorithms as well. The minimum free energy (mfe) required for RNA hybridization is shown in Figure 1C. No nucleotide variation in the MEN1 3’UTR, that could affect the miR-24-1 binding, was found at positions 599–605 nt in the analyzed DNA samples.

miR-24-1 Acts Directly at the MEN1 3’UTR

To confirm that miR-24-1 directly targets the highly-conserved sequence identified in the 3’UTR of MEN1 mRNA, a luciferase reporter assay was performed. 2’-O-methyl oligoribonucleotides were characterized as sequence-specific inhibitors of miRNA function and miRNA-direct RNA induced silencing complex (RISC) activity [1]. These molecules stoichiometrically bind and irreversibly inactivate miRNAs, providing a valuable tool to inhibit the function of a single miRNA both in vitro and in vivo.

To evaluate the degree of miRNA inhibition, the inhibition of miRNA-24-1 activity was verified by using pGL3/miR-24-1, a luciferase expression plasmid containing the complementary miR-24-1 binding sites. The luciferase expression plasmid containing the complementary miR-24-1 binding site (pGL3/24), and an analogous reporter with point substitutions disrupting the pairing to the miRNA seed of miR-24 acting as a negative control (pGL3/24MUT) were transfected in the human pancreatic neuroendocrine BON1 cells. The insertion of wild type sequences rendered the reporter sensitive to endogenous miR-24-1, with a reduction in luciferase activity when compared to the analogous mutated reporter (Fig. 2A). Thus, the effect of cellular endogenous miR-24-1 on translation of the luciferase mRNA was uniquely dependent

![Figure 1. Putative miR-24-1 binding site on MEN1 3’UTR mRNA. Panel A: Predicted secondary structure of MEN1 3’UTR mRNA; Panel B: The location of the putative miR-24-1 on MEN1 3’UTR target site and the comparison of nucleotides between the miR-24-1 seed-sequence and its target in four species are shown; Panel C: Predicted hybridization of miR-24-1 and MEN1 3’-UTR by using RNAhybrid software. The minimum free energy (mfe) required for RNA hybridization is shown. doi:10.1371/journal.pone.0039767.g001]
on the presence of the miR-24-1 cognate binding site within the 3'UTR, as expression of the luciferase reporter containing the mutant miR-24-1 binding site within the 3'UTR was unaffected by the presence of endogenous cellular miR-24-1. Co-transfection of the reporter plasmid with 2'-O-methyl RNA antisense miR-24-1 (pGL3/24 wt+2'-O-Me) enhanced the expression of the reporter construct, indicating inhibition of endogenous miRNAs. By contrast, co-transfection of the reporter plasmid with control antisense RNA (pGL3/24+mut 2'-O-Me) did not have the same effect (Fig. 2A). This antisense-based-loss of function assay showed inhibition of endogenous miR-24-1 at a functional level.

The effect of miR-24-1 antisense 2'-O-methyl RNA and pre-miR-24-1 treatment on endogenous miR-24-1 and menin protein levels in BON1 cells was also determined. Pre-miR, the miRNA precursor molecules, are small, chemically modified double-stranded RNA molecules designed to mimic endogenous mature miRNAs. After transfection of these RNA oligonucleotides in the human pancreatic neuroendocrine BON1 cells, the endogenous expression levels of miR-24-1, and menin were analyzed respectively by Northern and by Western blot. Selective inhibition of endogenous miR-24-1, by specific miR-24-1 antisense oligonucleotides (Fig. 2B), induced an increase in menin expression (Fig. 2C) when compared to the miR-24-1 mutated antisense oligonucleotides (Fig. 2B–C). Conversely, miR-24-1 reconstitution, by transfection with pre-miR-24-1 (Fig. 2B), induced a reduction of menin expression (Fig. 2 C) due to the increased expression of mature miR-24-1 (Fig. 2 B).

Figure 2. Luciferase assay and effects of miRNA inhibition/mimic. Panel A: WT reporter or mutated control luciferase plasmids were transfected into BON1 cells alone or with 2'-O-methyl miR-24-1 antisense RNA or 2'-O-methyl miR24-1 mutated antisense RNA (negative control). Reporter activities were measured after 2 days in differentiation media and normalized to Renilla luciferase activity. Bars indicate SD. *p<0.05 (paired Student’s t-test, n=3) with respect to the control negative sample. Panel B: Northern blot of mature miR-24-1 showing the selective inhibition of endogenous miR-24-1 by specific miR-24 antisense RNA reported to the mutated antisense RNA as well as by the miR-24-1 overexpression with pre-miR-24-1 compared to the negative pre-miR-C. Bars indicate SD. * Wt 24-1 2'-O-Me vs Mut W24-1 2'-O-Me (*p<0.05, paired Student’s t-test, n = 3) and # Pre-miR24-1 vs Pre-miR Control (p<0.05, paired Student’s t-test, n = 3). Panel C: Western blot analysis of menin expression performed to examine the effect of miR-24-1 on menin expression in BON1 cells treated with both 2'-O-methyl RNA and 2'-O-methyl pre-miR-mimic. An average of three experiments each performed in triplicate is presented. Bars indicate SD. *Wt 24-1 2'-O-Me vs Mut W24-1 2'-O-Me (*p<0.05, paired Student’s t-test, n = 3) and # Pre-miR24-1 vs Pre-miR Control (*p<0.05, paired Student’s t-test, n = 3). doi:10.1371/journal.pone.0039767.g002
Inverse Correlation of Menin Protein and miR-24-1 Expression in MEN1 Parathyroid Adenomatous Tissues that Conserved the Wild-type Allele

If miR-24-1 was a negative tissue-specific regulator of the menin oncosuppressor protein, then miR-24-1 should be over-expressed in MEN1 parathyroid adenomatous tissues versus sporadic non-MEN1 forms of parathyroid adenomas as well as in healthy parathyroid tissue. Through the analysis of the different tissues for LOH at both the MEN1 and miR-24-1 loci, four MEN1 parathyroid tumors showed LOH for the MEN1 allele (PA96, PA38, P49, and PA22), while four parathyroid tumors (PH2, PA86, PA62, and PA30) did not show MEN1-LOH, thus preserving the MEN1 wild-type allele (Table 1). Both mutational and LOH analyses of MEN1 allele in normal parathyroid and sporadic adenoma tissues showed homozygous wild-type MEN1 allele. LOH analysis for miR-24-1 gene did not show any LOH in any of the samples, as shown in Table 1. Northern blot analysis was performed to analyze the expression level of miR-24-1 in MEN1 parathyroid adenomas, in sporadic parathyroid adenomas and in one normal parathyroid tissue. As shown in Figure 3A, mature miR-24-1 was expressed only in MEN1 parathyroid adenoma tissues that conserved the wild-type allele (without MEN1-LOH), but not in the MEN1 parathyroid adenoma tissues that lost the MEN1 gene (with MEN1-LOH), as well as in sporadic parathyroid adenomas (Fig. 3A). The different expression levels of mature miR-24-1, consistent with results of the Northern blot analysis, was confirmed by real-time qRT-PCR (Fig. 3B). miR-24-1 is an Oncomir that Negatively Inhibits the Oncosuppressor Menin Protein After the First “Hit”

Those miRNAs whose expressions are increased in tumors may be considered oncogenes. These oncogene miRNAs are known as oncomirs and promote tumorigenesis by negatively inhibiting tumour suppressor genes. Indeed, miRNAs regulate gene expression through decreased translation, increased degradation of the target message, or both [4]. In order to check this hypothesis, we analyzed both the expression of MEN1 mRNA and menin protein in MEN1 and in sporadic parathyroid adenoma tissues. Real time qRT-PCR analysis of MEN1 mRNA expression showed that in MEN1 parathyroid adenomas that conserved one copy of the MEN1 wild-type allele, there was around 50% reduction of MEN1 mRNA expression with respect to the control samples (normal parathyroid tissue and sporadic adenomas with the homozygous wild-type MEN1 allele), while expression of MEN1 mRNA was strongly reduced in MEN1 parathyroid adenomas with LOH where wild-type MEN1 gene was lost (Fig. 4A). Western blot in lysates from both MEN1 parathyroid adenomas with MEN1-LOH and without MEN1-LOH showed almost undetectable levels of menin expression with respect to the sporadic forms and the normal parathyroid tissue (Fig. 4B). These data are in agreement with the absence of MEN1 mRNA expression of MEN1-LOH parathyroid adenomas and high MEN1 mRNA expression levels in the sporadic parathyroid adenomas and in normal parathyroid tissue (Fig. 4A), but for the 50% expression level shown by MEN1 parathyroid adenomas that conserved one wild-type copy of MEN1 gene (without MEN1-LOH), which should theoretically express half of the menin protein (Fig. 4A). These findings could be explained on the basis of a post-transcriptional negative control of MEN1 mRNA function in the presence of over-expressed miR-24-1 (Fig. 2A–B).

Table 1. Samples’ characteristics.

| Pathology                  | MEN1 mutation       | Tissue code | LOH | MEN1 (11q13) | LOH miR24-1 (9q22.32) |
|----------------------------|---------------------|-------------|-----|--------------|-----------------------|
| Normal parathyroid gland   | NO                  | P3          | NO  | NO           | NO                    |
| Parathyroid adenoma (NON MEN1) | NO                | PA2         | NO  | NO           | NO                    |
| Parathyroid adenoma (NON MEN1) | NO                | PA57        | NO  | NO           | NO                    |
| Parathyroid adenoma (NON MEN1) | NO                | PA93        | NO  | NO           | NO                    |
| Parathyroid hyperplasia (MEN1) | Frameshift, 1555insG, exon 10 | PH2         | NO  | NO           | NO                    |
| Parathyroid adenoma (MEN1) | Frameshift, 953delGA, exon 6 | PA30        | NO  | NO           | NO                    |
| Parathyroid adenoma (MEN1) | Frameshift, 317insS(GCCC), exon 2 | PA62        | NO  | NO           | NO                    |
| Parathyroid adenoma (MEN1) | Frameshift, 359del4 (GCTT), exon 2 | PA86        | NO  | NO           | NO                    |
| Parathyroid adenoma (MEN1) | Nonsense, Gln508stop, exon 10 | PA22        | YES | NO           | NO                    |
| Parathyroid adenoma (MEN1) | Frameshift, 335delA, exon 2 | PA49        | YES | NO           | NO                    |
| Parathyroid adenoma (MEN1) | Nonsense, Gln508stop, exon 10 | PA83        | YES | NO           | NO                    |
| Parathyroid adenoma (MEN1) | Splicing 765-1(G→AA), intron3-exon 4 | PA96        | YES | NO           | NO                    |

doi:10.1371/journal.pone.0039767.t001

Negative Regulatory Loop between miR-24-1 and Menin Exists in MEN1 Parathyroid Adenoma Tissues without LOH

Because regulatory feedback loops between miRNAs and their targets, mainly TFs, have been shown in several reports [17–19], we hypothesized that the data reported above indicated the possibility that, in MEN1 parathyroid adenoma tissues without LOH, miR-24-1 and menin are linked by a negative regulatory loop. To elucidate the transcriptional regulators involved in miR-24-1 gene expression, we screened for transcriptional factor binding sites in miR-24-1. Menin-binding sites in the promoter of miR-24-1 were predicted by using the Transcription Element Search Software program (http://www.cbil.upenn.edu/cgi-bin/tess/tess), but we could not find any consensus menin binding sites. That is because, although menin is proven to be a TF [12,13], there are no data in the database used by prediction softwares. To check this hypothesis, chromatin immunoprecipitation (ChIP) assay for menin was performed using parathyroid tissues from MEN1 patients. Co-precipitated DNA was analyzed by amplifying the genomic region containing miR-24-1 promoter region by real time PCR (Fig. 5). Occupancy of miR-24-1 promoter region was observed only in MEN1 parathyroid adenoma tissues without LOH (that conserved the wild-type copy of MEN1 allele), when...
compared to MEN1 parathyroid adenoma tissues with LOH and to control IgG (Fig. 5). These results indicate that menin occupies the miR-24-1 gene promoter, thus inducing its expression. As menin is a positive regulator of miR-24-1, while miR-24-1 negatively regulates the expression of menin, we conclude that menin and miR-24-1 form a “negative feedback loop” in the MEN1 parathyroid adenoma tissues without LOH (which thus still have one copy of the wild type allele).

Discussion

In this study, we showed that in MEN1 syndrome, a rare complex tumor-predisposing disorder inherited in an autosomal dominant manner, the onset and progression of disease, after the first inherited “hit” is under the control of a “negative feedback loop” between menin and miR-24-1. This mechanism mimics the second somatic “hit” of tumor suppressor inactivation, thus indicating a potential mechanism for tissue-selective tumorigenesis in this hereditary tumor syndrome. Indeed, the main question regarding the pathogenetic basis of MEN1 syndrome is its predominant endocrine tumoral phenotype, with variable clinical manifestations not-related to the type of MEN1 gene inactivating mutations. Candidate tissue-specific regulators may include miRNAs and TFs. We previously showed that in primary cultures of fibroblasts from MEN1 patients wild type MEN1 gene- encoded mRNAs were expressed, whereas mutant alleles were partially degraded by a nonsense-mediated mRNA decay (NMD) pathway, suggesting a mechanism of feedback compensation for allelic loss by the up-regulation of wild-type menin expression at post-transcriptional level [13]. We also showed that menin forms a ribonucleoprotein structure in which multiple mRNAs should be coordinately regulated by RNA binding proteins and miRNAs [13]. This mechanism could be a way to control the haploinsufficiency that occurs when one allele is insufficient to confer the full functionality produced from two wild-type alleles.

In the present study, we analyzed the expression profile of miR-24-1 in parathyroid samples from MEN1 patients, with different MEN1 mutations, in which the main difference was the MEN1 LOH or the maintenance of the wild type MEN1 allele. Analysis of miR-24-1 LOH showed no LOH for all the analyzed samples. While parathyroid adenomas from patients that lost both MEN1 alleles showed no expression of MEN1 mRNA, of menin, or of miR-24-1, MEN1 parathyroid adenomas from patients that maintain one wild type copy of the MEN1 gene showed, as
expected, a reduced expression of MEN1 mRNA, but no expression of menin, while miR-24-1 was expressed. Thus, the induction of miR-24-1 seems to depend on transcriptional expression of MEN1 mRNA. The ChIP study demonstrated the association of menin with the miR-24-1 promoter, suggesting that the pri-miR-24-1 transcription was regulated by menin. The same mechanism does not seem to be involved in the sporadic parathyroid adenomas which usually occur later in the life of patients.

We showed that menin is the target of one miRNA, the miR-24-1, that directly targets the highly-conserved sequence identified in the 3’UTR of MEN1 mRNA, thus offering an answer to the endocrine tissue-specificity of MEN1 tumors. Results from this study suggested that in MEN1 syndrome, after the first inherited germinal “hit”, the somatic onset and progression of neoplasia could be under the control of a “negative feedback loop” between menin protein and miR-24-1. We hypothesized that this regulatory network could mimic and substitute the second somatic “hit” of tumor suppressor inactivation in tissues in which MEN1 LOH has not yet occurred or could represent an intermediate step before the MEN1 LOH (Fig. 6). This mechanism should explain the proliferative changes in the neuroendocrine cells that could precede neoplasia. In the duodenum and the pancreas, the MEN1 gene-associated germline mutation causes hyperplasia of gastrin, somatostatin and glucagon-secreting cells, resulting in multifocal development of tumors [20]. Indeed, these tumors show allelic deletion of the MEN1 gene, whereas the precursor lesions retain their heterozygosity [20]. In MEN1 the mechanism leading to neuroendocrine hyperplasia could be explained by the proposed “negative feedback loop” between menin and miR-24-1 acting as “homeostatic regulatory network” that need to be “broken” to induce the somatic “hit” and, consequently, to the neoplasia.

Many human genetic diseases result from loss-of-function germline mutations in one of the two homologous gene loci. These are often referred to as autosomal dominant diseases because of frequent phenotypic dominance of the mutated allele over the wild type allele during transmission along generations. There is presently one prevailing theory explaining the autosomal dominant expression of these diseases. This explanation originates from the Knudson two-hit theory of hereditary cancers, where loss of

Figure 4. Expression analysis of menin protein and MEN1 mRNA. Panel A: Real time quantitative RT-PCR analysis of MEN1 mRNA in normal parathyroid tissue, in MEN1 parathyroid adenomas, and in non-MEN1 parathyroid adenomas. An average of three experiments each performed in triplicate; and panel B: Densitometric Western blot analysis (NIH-Image) in normal parathyroid tissue, in MEN1 parathyroid adenomas and in non-MEN1 parathyroid adenomas. Density ratio menin/beta-actin: bar diagram. Bars indicate SD. * \( p < 0.05 \) (paired Student’s t-test, \( n = 3 \)) with respect to the control sample, the normal parathyroid tissue.

doi:10.1371/journal.pone.0039767.g004
heterozygosity or occurrence of somatic mutations impairs the function of the wild-type copy [21–24]. While this somatic second hit may be sufficient for stable disease states, it is often difficult to determine if their occurrence necessarily marks the initiation of disease progression [25,26]. Stochastic factors are likely to contribute to the characteristics of variable time of onset and incomplete penetrance of many autosomal dominant diseases [27,28]. GRNs involving positive and negative feedbacks could control the effects of noise, by buffering its impact on gene expression [29]. In GRNs, TFs and miRNAs may reciprocally regulate one another to form “feedback loops”, or alternatively, both TFs and miRNA may regulate their target genes and form “feed-forward loops” [29]. Feedback loops are network structures that appear to have two functions in biological systems: they act as rapid switches to turn on a process [30,31] and they act as noise buffers to enable a system to respond to long term signal changes [31]. Particularly, “negative feedback loops” potentially function to fine-tune gene expression and to maintain precise steady state levels of both components of the loop [29] and can result in oscillatory expression of both components, which depends on additional input signals [32]. We could hypothesize that the “negative feedback loop” between menin and miR-24-1 works buffering external and/or internal influences, as hormones and/or environmental factors. Epigenetic perturbations of this system could indeed drive the MEN1 tumorigenesis, as also supported by the individual clinical manifestation in MEN1 patients, independent on the type of MEN1 gene mutation.

In conclusion, we showed that MEN1 syndrome could originate from mechanisms alternative to LOH. These events are under the control of a GRN, where miRNA-24-1 represents a strategic target to develop a therapeutic silencing antagomir to control MEN1 tumorigenesis progression [33].

Materials and Methods

Tissues Collection

We collected specimens from patients who underwent surgical parathyroid excision for benign adenomas; in particular we have obtained parathyroid tissues from MEN1 patients, exhibiting different MEN1 gene mutations, as well as sporadic parathyroid adenoma samples from non-MEN1 patients (Table 1). Normal human parathyroid tissue used as healthy control was obtained by patients operated for thyroid carcinoma and pooled from three different cases. The data were analyzed anonymously and we used tissues collected before the establishment of “AOUC Ethics Committee”.

Cell Cultures

Human pancreatic neuroendocrine BON1 tumour cells were kindly provided by Dr. Auernhammer (Munich, Germany). BON1 cells were cultured in DMEM/F12 (1:1) medium (Life Technologies, Invitrogen, Foster City, CA USA) supplemented with 10% FCS., 1% penicillin/streptomycin (Life Technologies, Invitrogen), and 0,4% amphotericin (Biochrom, Cambridge, UK) in a 5% CO2 atmosphere.

MEN1 Gene Mutational Analysis

Genomic DNA of the MEN1 patients was extracted from peripheral blood leukocytes using a microvolume silica membrane-based column system according to the manufacturer’s instructions (NucleoSpin Blood Quick Pure; Macherey-Nagel, Easton, PA, USA). Mutational analysis of the encoding regions (exons 2–10) and of the intron-exon junctions of the MEN1 gene was performed by PCR-based direct sequencing.

Loss of Heterozygosity Analysis

PCR-based microsatellite analysis for Loss of Heterozygosity (LOH) in the MEN1 region was performed in parathyroid tissue DNA samples versus blood DNA samples. LOH analysis was
performed using four specific microsatellite markers (D11S480, PYGM, D11S449, and D11S913) flanking the 11q12-13 locus. PCR-based microsatellite analysis for LOH in the 9q22.32 region, containing the human miR-24-1 gene, was performed in genomic DNA from parathyroid tissues versus blood-derived genomic DNA. LOH analysis was performed using 4 specific microsatellite markers (D9S167, D9S278, D9S283, D9S280) flanking the 9q22.32 locus.

An independent PCR amplification was performed for each microsatellite in a final volume of 12.5 μl using PuReTaq Ready-To-Go PCR beads (GE Healthcare, Buckinghamshire, UK). An aliquot of each amplification product was denatured at 95°C for 5 min, in a solution of formamide and GENESCAN 400HD [ROX] size standard (Applied Biosystems), and then analyzed on the ABI Prism 3100 Genetic Analyzer (Applied Biosystems) by Genescan® analysis software.

MicroRNA Target Prediction

The candidate targets of miR24-1 were identified based on a conservative intersection of the following microRNAs target prediction tools: TargetScan (http://genes.mit.edu/targetscan), Miranda (http://www.microrna.org/), and Pictar (http://pictar.bio.nyu.edu/). The minimum free energy required for RNA hybridization was predicted by using RNAhybrid software (http://bibiserv.techfak.uni-bielefeld.de/).

MEN1 3'UTR Region Sequencing

The 3'UTR of the MEN1 gene was analyzed, in blood-derived genomic DNA from all the subjects included in this study, by PCR-based direct and reverse sequencing for the screening of possible polymorphic variants, in the two binding sites to miR-24-1 evidenced by prediction tools (position 59–65 of MEN1 3'UTR and position 599–605 of MEN1 3'UTR), that could affect the miR-24-1-MEN1 mRNA bound.

Oligoribonucleotides, Reporter Plasmids and Luciferase Assays

2'-O-methyl oligoribonucleotides miR-24-1 antisense, 5'-CU-GUCCUGCGAUAUUGGCC-3'; miR-24-1 antisense mutated, 5'-CU-GUCCUGCGAUAUUGGUU-3') were synthesized by IBA (Gottingen, Germany). Reporter constructs that contain a miR-24-1 binding site (''pGL3-24-1'') or a mismatch sequence (''pGL3-24-1MUT'') in the 3'UTR of MEN1 mRNA were constructed by amplification of the full-length 3'UTR MEN1 (832 nt) using the following primers: 5'-CAGAGATCTAAGTCGTGTGAAATCATGTG-3 (FW), 5'-TAAGTCGAACAGGGTTTTCCAAGTCTA-3 (RV) cloned into the XbaI-site of pGL3 (Promega, Madison, WI, USA), checked for orientation, sequenced and named.

Two hundred ng of Reporter or control plasmid (plus 80 ng pRL-null; Promega; Madison, WI, USA) were transfected, alone.
or in combination with 40 pmol of 2'-O-methyl oligoribonucleotides, in the BON1 cells, using Lipofectamine (Invitrogen). Luciferase assays were performed 48 h after transfection using the Dual Luciferase Reporter Assay System (Promega). Firefly luciferase activity was normalized to renilla luciferase activity for each transfected well. Each transfected well was assayed in triplicate.

Transient Transfections
For the transfection experiments, a miR-24-1 precursor (pre miR-24-1) and a pre-miR negative control (pre C; random sequence pre-miR molecules extensively tested in human cell lines and tissues and validated to do not produce identifiable effects on known miRNAs function) were obtained by Ambion (Applied Biosystems). 2'-O-Me antisense miR-24-1 and miR-24-1 antisense mutated were described above. BON1 cells were transfected with RNAs (200 pmol) by using Lipofectamine 2000 (Invitrogen) according to the manufacturer’s instructions. Cells were harvested 48 h after initial transfection and proteins and RNAs were isolated by using “PARIS” (Ambion).

Northern Blot Analysis
Total RNA was isolated with Trizol reagent (Invitrogen) according to the manufacturer’s instructions. For miRNA Northern blots, 15 μg of total RNA were separated on 15% denaturing polyacrylamide gels, electro-transferred to GeneScreen Plus membranes (PerkinElmer, Waltham, MA, USA), and hybridized using UltraHyb-Oligo buffer (Applied Biosystems) at 42°C overnight. Oligonucleotides, complementary to mature miRNAs, were 32P end-labeled with T4 Kinase (Roche Diagnostics, Indianapolis, IN, USA) and used as probes. Sequence Pre-miR molecules extensively tested in human cell lines and tissues and validated for their valuable comments.

Chromatin Immunoprecipitation
Chromatin immunoprecipitation (ChIP) was used to detect protein-DNA interactions. Tissues ChIP analysis was performed with a commercially available EpiQuik Tissue Chromatin Immunoprecipitation (ChIP) Kit in accordance with the manufacturer’s instructions. The chromatin fraction was immunoprecipitated overnight at 4°C using anti-menin (BL342) polyclonal antibody (Bethyl) and anti-IgG antibodies, followed by stringent washing and elution. Quantitative PCR amplification analysis was performed in a total volume of 25 μl with specific primers. The forward and reverse primers used for each gene were as it follows:

5’-AGCAGCTAGCAGGTTGATGT-3’; 5’-CATGGGAA-GAACAGAGGATGA-3’.

Western Blotting
Cell and tissue lysates were prepared by the PARIS purification kit. Protein concentrations were determined by the BCA protein assay (Pierce, Rockford, IL, USA) using bovine serum albumin as the standard protein. Fifteen μg of each cell extract protein were denatured 10 minutes at 95°C in a volume of 95% Laemmli Sample Buffer (Bio-Rad, Hercules, CA, USA) and 5% beta-mercaptoethanol solution. Proteins were separated by SDS-12% polyacrylamide gel electrophoresis. The separated protein bands were transferred electrophoretically to a nitrocellulose membrane (Optitran BA-S 83, Schleicher & Schuell, Dassel, Germany) for 1 hour in a Mini Trans-blot electrophoretic transfer cell (Bio-Rad) at 100 V. Filters were blocked for 1 hour at room temperature in a blocking solution of PBS, 0.1% tween 20 and 2% ECL Advance blocking agent (Amersham Biosciences, Little Chalfont, UK). To evaluate menin expression, the blocked membrane was incubated with rabbit anti-menin (BL342) polyclonal antibody (Bethyl) for 1 hour at room temperature (1:1000 dilution of stock in blocking solution), washed 4 times for 5 minutes each with a solution of PBS and 1% tween 20, incubated with an anti-rabbit horseradish peroxidase-conjugated secondary antibody (Santa Cruz, CA, USA) for 1 hour at room temperature (1:2000 dilution of stock in blocking solution), then washed 4 times for 5 minutes each with a solution of PBS and 1% tween 20 and finally washed once with PBS. Detections of membrane-bound anti-menin antibody were performed by chemiluminescence. Beta-actin was used as a housekeeping protein.

Statistical Analysis
Data are expressed as mean ± SD. All blots represent at least three separate experiments. Data shown were done in triplicate for each experiment, and are representative of three or more experiments. Comparisons were made by using a two-tailed t test or one-way ANOVA for experiments with more than two subgroups. Probability values were considered statistically significant at p<0.05. Due to the rarity of MEN1 syndrome, the current parathyroid sample size is relatively small, thus the potency of the current statistical analysis could be reduced.

Acknowledgments
Authors are grateful to Dr. Alberto Falchetti and Prof. Pier Paolo Pandolfo for their valuable comments.

Author Contributions
Conceived and designed the experiments: EL. Performed the experiments: EL FM GG. Analyzed the data: EL FG. Contributed reagents/materials/analysis tools: GG LC. Wrote the paper: EL MLB.
MicroRNA Post-Transcriptional Regulation of Menin

References

1. Flynt A-S, Lai E-C (2008) Biological principles of microRNA-mediated regulation: shared themes amid diversity. Nat Rev Genet 9: 831–842.
2. Saini H-K, Griffiths-Jones S, Enright A-J (2007) Genomic analysis of human microRNA transcripts. Proc Natl Acad Sci USA 104: 17719–17724.
3. Michael M-Z, O'Connor S-M, van Holst Pellekaan N-G, Young G-P, James R-J (2003) Reduced accumulation of specific microRNAs in colorectal neoplasia. Mol Cancer Res 1: 682–691.
4. Calin G-A, Liu CG, Sevignani C, Ferracin M, Felli N, et al. (2004) MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukaemias. Proc Natl Acad Sci USA 101: 11755–11760.
5. Calin G-A, Ferracin M, Cimmino A, Di Leva G, Shimizu M, et al. (2005) A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukaemia. N Engl J Med 353: 1793–1801.
6. Eswara P-S, Tan W, Sun L, Chadburn A, Li Z, Gomez MF, et al. (2005) Accumulation of miR-155 and BRC RNA in human B cell lymphomas. Proc Natl Acad Sci USA 102: 3627–3632.
7. Takamizawa J, Konishi H, Yanagiwaka K, Tumida S, Osada H, et al. (2004)Reduction of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res 64: 3753–3756.
8. Iorio M-V, Ferracin M, Liu CG, Veronese A, Spizzo R, et al. (2005) MicroRNA gene expression deregulation in human breast cancer. Cancer Res 65: 7065–7070.
9. Ciafre S-A, Galardi S, Mangiola A, Ferracin M, Liu CG, et al. (2005) Extensive modulation of a set of microRNAs in primary glioblastoma. Biochem Biophys Res Commun 334: 1351–1358.
10. Chan J-A, Krichevsky A-M, Kosik K-S (2005) MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res 65: 6029–6033.
11. Calin G-A, Sevignani C, Dumitru CD, Hyslop T, Noch E, et al. (2004) Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA 101: 2999–3004.
12. Falchetti A, Marini F, Luzi E, Giusti F, Cavalli L, Cavalli T, et al. (2009) Multiple endocrine neoplasia type 1 (MEN1): not only inherited endocrine tumors. Genet Med 11: 823–833.
13. Falchetti A, Marini F, Tognarini I, Carbonell Sala S, Galli G, et al. (2010) Ribozyme-mediated compensatory induction of menin-oncospirrepressor function in primary fibroblasts from MEN1 patients. Cancer Gene Ther 2010; 17: 814–825.
14. Keese J-D (2010) Minireview: global regulation and dynamics of ribonucleic acid. Endocrinology 151: 1391–7.
15. Agarwal S-K, Impye S, McWeeney S, Scacheri PC, Collins FS, et al. (2007) Distribution of menin-occupied regions in chromatin specifies a broad role of menin in transcriptional regulation. Neoplasia 9: 101–107.
16. Herranz H, Cohen S-M (2010) MicroRNAs and gene regulatory networks: managing the impact of noise in biological systems. Genes Dev 24: 1339–1344.
17. Petrovics G, Visone R, Orelli MR, Shah MH, Nicoloso MS, et al. (2008) E2F1-regulated microRNAs impair TGFb-dependent cell-cycle arrest and apoptosis in gastric cancer. Cancer Cell 13:272–286.
18. Yang X, Feng M, Jiang X, Wu Z, Li Z, et al. (2009) miR-449a and miR-449b are direct transcriptional targets of E2F1 and negatively regulate pRb-E2F1 activity through a feedback loop by targeting CDK6 and CDC25A. Genes Dev 23: 2388–2393.
19. Xu X, Papageorgopoulos T, Pan G, Thomson J-A, Kosik K-S (2009) MicroRNA-155 regulates OCT1, SOX2, and KLF4 and represses pluripotency in human embryonic stem cells. Cell 137: 647–658.
20. Anlauf M, Perren A, Kloppe KG (2007) Endocrine precursor lesions and microadenomas of the duodenum and pancreas with and without MEN1—criteria, molecular concepts and clinical significance. Pathobiology 74: 279–294.
21. Knudson A-G (2001) Two genetic hits (more or less) to cancer. Nat Rev Cancer 1:157–162.
22. Knudson A-G (1996) Hereditary cancer: two hits revisited. J Cancer Res Clin Oncol 122:135–140.
23. Knudson A-G (1971) Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA 68:820–823.
24. Soto A-M, Sommerschien C (2004) The somatic mutation theory of cancer: growing problems with the paradigm? Bioessays 26:1097–1107.
25. Sommerschien C, Soto A-M (2009) Somatic mutation theory of carcinogenesis: why it should be dropped and replaced. Mol Carcinog 29:205–211.
26. Venitt R-A (2002) Exploring the etiology of haploinsufficiency. Bioessays 24:175–184.
27. Ogino S, Wilson R-B, Gold B, Fodor P (2007) Bayesian risk assessment in genetic testing for autosomal dominant disorders with age-dependent penetrance. J Genet Couns 16:29–39.
28. Milo R, Shen-Orr S, Itzkovitz S, Kashtan N, Chklovskii D, et al. (2002) Network motifs: Simple building blocks of complex networks. Science 298: 824–827.
29. Martinez N-J, Walhout A-J (2009) The interplay between transcription factors and microRNAs in genome-scale regulatory networks. Bioessays 31: 435–445.
30. Brandman O, Ferrell J-E, Li R, Meyer T (2005) Interlinked fast and slow positive feedback loops drive reliable cell decisions. Science 310: 496–498.
31. Hornung G, Barkai N (2008) Noise propagation and signaling sensitivity in biological networks: a role for positive feedback. PLoS Comput Biol 4: e8.
32. Dublanche Y, Michalodimitrakis K, Kämmerer N, Foglierini M, Serrano K (2006) Noise in transcriptional feedback loops: simulation and experimental analysis. Mol Syst Biol 2: 41.
33. Galasso M, Elena Sama M, Volinia S (2010) Non-coding RNAs: a key to future personalized molecular therapy? Genome Med 2: 1.